ReviewBlood reviews2011
JAK2 inhibitors: what's the true therapeutic potential?
Review in Blood reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 68 citations in OpenAlex.
- AI and experimental convergence: a synergistic pathway to JAK2 inhibitor discovery.Acta pharmacologica Sinica · 2026Article
- Antitumor Activity of Tetrahydro-β-carboline Derivatives via Inhibition of Kinesin Spindle Protein: Validation by Molecular Docking, Molecular Dynamics, and In Vitro Assays.International journal of molecular sciences · 2025Article
- Classical Angiogenic Signaling Pathways and Novel Anti-Angiogenic Strategies for Colorectal Cancer.Current issues in molecular biology · 2022Review
- Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions.Frontiers in pharmacology · 2018Article
- How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Scientific reports · 2017Article
- Research and progress on ClC‑2 (Review).Molecular medicine reports · 2017Review
- Review
- The Chemopreventive Phytochemical Moringin Isolated from Moringa oleifera Seeds Inhibits JAK/STAT Signaling.PloS one · 2016Article
- Up-regulation of Kv1.3 channels by janus kinase 2.The Journal of membrane biology · 2015Article
- Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text Mining.BioMed research international · 2015Article
- Mpl traffics to the cell surface through conventional and unconventional routes.Traffic (Copenhagen, Denmark) · 2014Article
- Down-regulation of the epithelial Na⁺ channel ENaC by Janus kinase 2.The Journal of membrane biology · 2014Article
- Article
- The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.PloS one · 2014Article
- Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia.Nature medicine · 2013Article
- Downregulation of KCNQ4 by Janus kinase 2.The Journal of membrane biology · 2013Article
- Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes.Immunogenetics · 2013Article
- Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population.PloS one · 2013Article
- Downregulation of the creatine transporter SLC6A8 by JAK2.The Journal of membrane biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Physicians treating patients with the classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available. Spurred by the discovery of activating mutation of the JAK2 tyrosine kinase (JAK2 V617F mutation) in patients with Ph-negative MPNs several years ago, several JAK2 inhibitors were synthesized and are currently undergoing clinical trials in patients with PMF, PV and ET. Initial results from these studies have shown that these drugs can markedly reduce spleen size and alleviate constitutional symptoms, increase weight and improve exercise capacity in MF patients, thus improve quality of their life, which is significant clinical benefit. In ET and PV JAK2 inhibitor therapy may efficiently control blood cell count, as well as improve splenomegaly and control disease related symptoms. JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET. In this article we will review the current evidence regarding the role of JAK2 mutations in the pathogenesis of Ph-negative MPNs and summarize results from the most recent clinical trials with JAK2 inhibitors in these disorders. JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.